Xuanbai Yiqi Decoction for Sepsis: A Randomized Controlled Trial
Key facts
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 280 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Xuanbai Chengqi Decoction
- Xuanbai Chengqi Decoction; Forest-Cultivated Ginseng
- Xuanbai Yiqi Decoction
- Inactive Chinese Herbal Decoction Placebo
- Record updated
- 28 October 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age ≥18 years and ≤80 years
- Patients meeting the updated diagnostic criteria for sepsis (Sepsis-3), defined as infection-induced organ dysfunction with an increase of ≥2 points from baseline in the Sequential Organ Failure Assessment (SOFA) score (see table)
- Provision of signed informed consent. Patients must meet all of the above criteria to be eligible for inclusion
Who cannot take part
- Concurrent autoimmune disease
- Concurrent psychiatric disorders
- Patients with advanced-stage cancer
- Chronic failure of the heart, lung, liver, or kidney before admission, defined as:; Chronic heart failure: long-term use of a left ventricular assist device (LVAD) or inotropic agents such as milrinone; ii. Chronic respiratory failure: long-term use of a home non-invasive oxygen therapy device; iii. Liver function classified as Child-Pugh class C; iv. Chronic renal failure: requiring regular hemodialysis
- Known allergic diathesis or hypersensitivity to any study drug. Patients meeting any of the above criteria will be excluded
- Pregnant or breastfeeding women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. Multiple organ dysfunction syndrome (MODS) is the leading cause of sepsis-related death. Early in sepsis, intestinal barrier injury and gut microbiota dysbiosis occur, and gut-derived toxins and inflammatory cytokines act on the lungs and the whole body via the gut-liver-lung axis, representing an important pathophysiological mechanism. In the intermediate and late stages of the disease, patients generally develop immunosuppression. Our team intends to establish a Traditional Chinese Medicine (TCM)-based comprehensive intestinal management protocol. Xuanbai Chengqi Decoction will be used in early sepsis. In the intermediate-to-late stage, when immunosuppression occurs (monocytic HLA-DR [mHLA-DR] expression <30%, decreased CD3+ and CD4+ lymphocyte counts, and a reduced CD4+/CD8+ ratio), Xuanbai Yiqi Decoction supplemented with forest-cultivated ginseng will be used, combined with acupuncture, to protect multiple organs including the intestine and lungs and to modulate immunity.This is a prospective, randomized, double-blind, placebo-controlled clinical trial enrolling 280 patients with sepsis hospitalized in the Department of Emergency Medicine and the Department of Critical Care Medicine at Ruijin Hospital. Patients with sepsis who meet all inclusion and exclusion criteria at admission will be randomly assigned to the control group, Xuanbai Chengqi Decoction group, Xuanbai Chengqi Decoction plus forest-cultivated ginseng group, or Xuanbai Yiqi Decoction group. The granules will be dissolved in 100 mL of warm water and administered once daily via a nasogastric tube for 7 consecutive days, in addition to standard sepsis treatment.The primary outcome is improvement in the Sequential Organ Failure Assessment (SOFA) score at day 7 (a measure of organ function). Secondary outcomes include disseminated intravascular coagulation (DIC) score, coagulation tests, endothelial injury and platelet markers, inflammatory markers, 28-day mortality, intensive care unit (ICU) and hospital length of stay, and adverse events.The study is funded by Ruijin Hospital and is conducted as an investigator-initiated trial.
The 4 groups in the trial
- Xuanbai Chengqi Decoction GroupTreatment being tested
In addition to standard Western medical treatment for sepsis, participants receive Xuanbai Chengqi Decoction on days 1-7 after enrollment. The decoction consists of raw gypsum 30 g, raw rhubarb 12 g, bitter apricot seed 18 g, and Trichosanthes peel 18 g; it is decocted in water to 100 mL and administered twice daily.
Treatment: Xuanbai Chengqi Decoction
- Xuanbai Chengqi Decoction + Forest-Cultivated Ginseng GroupTreatment being tested
In addition to standard Western medical treatment for sepsis, participants receive Xuanbai Chengqi Decoction on days 1-7 after enrollment, with concurrent monitoring of immune function. If immunosuppression occurs (mHLA-DR \<30%, decreased CD3+ and CD4+ lymphocytes, and reduced CD4+/CD8+ ratio), forest-cultivated ginseng 9 g is added to Xuanbai Chengqi Decoction. The modified decoction consists of raw gypsum 30 g, raw rhubarb 12 g, bitter apricot seed 18 g, Trichosanthes peel 18 g, and forest-cultivated ginseng 9 g; it is decocted in water to 200 mL and administered once daily.
Treatment: Xuanbai Chengqi Decoction; Forest-Cultivated Ginseng
- Xuanbai Yiqi Decoction GroupTreatment being tested
In addition to standard Western medical treatment for sepsis, participants receive Xuanbai Yiqi Decoction on days 1-7 after enrollment. The decoction consists of raw gypsum 30 g, raw rhubarb 12 g, bitter apricot seed 18 g, Trichosanthes peel 18 g, and forest-cultivated ginseng 3 g; it is decocted in water to 200 mL and administered once daily.
Treatment: Xuanbai Yiqi Decoction
- Control GroupPlacebo, for comparison
In addition to standard Western medical treatment for sepsis, participants receive an inactive Chinese herbal decoction placebo on days 1-7 after enrollment. The placebo is designed to simulate odor and to ensure physicochemical properties comparable to the investigational drugs, with the same administration route and treatment duration.
Treatment: Inactive Chinese Herbal Decoction Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Xuanbai Yiqi Decoction in Patients With Sepsis: a Randomized, Double-blind, Controlled, Four-arm, Prospective Trial
- Criteria questions
- Built from NCT07902024, who can take part
- Record updated
- 28 October 2026